Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 219-226

  Arenas Pinto, Alejandro ^a,b   Grant, Alison ^c   Bhaskaran, Krishnan ^c   Copas, Andrew ^a   Carr, Andrew ^d   Worm, Signe W ^e   Martinez, Esteban ^f   Reiss, Peter ^g   Dunn, David ^h   Weber, Rainer ⁱ   Hoy, Jennifer ^j   Weller, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CD4 ANTIGEN; DIDEOXYNUCLEOTIDE; LACTIC ACID;

ADULT; AGE; ARTERIAL PH; ARTICLE; BICARBONATE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FATALITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79953213302     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1739     Document Type: Article

References (27)

1. Imhof A, Ledergerber B, Gunthard HF, et al. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infect Dis 2005; 41:721-728.
2. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254-260. (Pubitemid 47041019)
3. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760. (Pubitemid 47235489)
4. Geddes R, Knight S, Moosa MY, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96:722-724. (Pubitemid 44336098)
5. Stead D, Osler M, Boulle A, et al. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther 2008; 13:937-943.
6. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005; 24:5-15.
7. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169. (Pubitemid 43786105)
8. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis 2003; 36 Suppl 2:S96-S100. (Pubitemid 36408118)
9. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002; 29 Suppl 1:S28-S40. (Pubitemid 34163470)
10. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15:23-29. (Pubitemid 34112389)
11. Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79:340-343.
12. Mégarbane B, Brivet F, Guerin JM, et al. Lactic acidosis and multiorgan failure secondary to antiretroviral treatments in HIV-infected patients. Presse Med 1999; 28:2257-2264. (Pubitemid 30020021)
13. Falcó V, Rodriguez D, Ribera E, et al. Severe nucleoside- associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838-846. (Pubitemid 34194856)
14. Songa PM, Castelnuovo B, Mugasha EB, et al. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007; 45:514-517. (Pubitemid 47204473)
15. Manosuthi W, Prasithsirikul W, Chumpathat N, et al. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis 2008; 12:582-586.
16. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21:2455-2464.
17. Cox DR, Snell EJ. Analysis of binary data. Boca Raton: Chapman & Hall/CRC 1989.
18. Osler M, Stead D, Rebe K, et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010; 11:121-129.
19. Hocqueloux L, Alberti C, Feugeas JP, et al. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med 2003; 4:18-23. (Pubitemid 37161532)
20. Gérard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14:2723-2730. (Pubitemid 32118726)
21. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-1349. (Pubitemid 34722065)
22. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723. (Pubitemid 32423219)
23. Wohl DA, Pilcher CD, Evans S, et al. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr 2004; 35:274-278. (Pubitemid 38280653)
24. Gerard Y, Yazdanpanah Y, Ajana F, et al. Use of stavudine is associated with a high risk of severe hyperlactataemia in black women. Antivir Ther 2005; 10 Suppl 3:L42-L43.
25. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-275. (Pubitemid 35278626)
26. Ivers LC, Mukherjee JS. Point of care testing for antiretroviral therapy-related lactic acidosis in resourcepoor settings. AIDS 2006; 20:779-780. (Pubitemid 43884308)
27. Mathee S, Abrahams M, Jackson N, et al. Point of care lactate testing is an effective measure in supporting the WHO first-line regimen in settings with a high incidence of stavudine-related toxicity. XVI International AIDS Conference. 13-18 August 2006, Toronto, ON, Canada. Abstract MOPE0085.